Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2020-01-32694,2020,Manchanda 2020 Cancers (Basel),8700,population-based brca1/brca2 mutation testing VERSUS Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing IN Specific disease- breast cancer; Age- Adult; Gender- Female; Country- Brazil.,32708835,Specific disease- breast cancer; Age- Adult; Gender- Female; Country- Brazil.,population-based brca1/brca2 mutation testing,Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple  Countries and Health Systems.,Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing,NE
2020-01-32694,2020,Manchanda 2020 Cancers (Basel),Cost-Saving,population-based brca1/brca2 mutation testing VERSUS Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing IN Specific disease- breast cancer; Age- Adult; Gender- Female; Country- Netherlands.,32708835,Specific disease- breast cancer; Age- Adult; Gender- Female; Country- Netherlands.,population-based brca1/brca2 mutation testing,Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple  Countries and Health Systems.,Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing,SE
2020-01-32694,2020,Manchanda 2020 Cancers (Basel),Cost-Saving,population-based brca1/brca2 mutation testing VERSUS Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing IN Specific disease- breast cancer; Age- Adult; Gender- Female; Country- United Kingdom.,32708835,Specific disease- breast cancer; Age- Adult; Gender- Female; Country- United Kingdom.,population-based brca1/brca2 mutation testing,Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple  Countries and Health Systems.,Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing,SE
2020-01-32694,2020,Manchanda 2020 Cancers (Basel),Cost-Saving,population-based brca1/brca2 mutation testing VERSUS Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing IN Specific disease- breast cancer; Age- Adult; Gender- Female; Country- United States.,32708835,Specific disease- breast cancer; Age- Adult; Gender- Female; Country- United States.,population-based brca1/brca2 mutation testing,Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple  Countries and Health Systems.,Standard/Usual Care- Family history based BRCA1/BRCA2 mutation testing,SE
2020-01-30852,2020,Rens 2020 Clin Infect Dis,1800,pharmacogenomic-guided treatment VERSUS Standard/Usual Care- Standard treatment IN Specific disease- tuberculosis ; Age- Unknown; Gender- Both; Country- South Africa; Other- drug-resistant tuberculosis.,31905381,Specific disease- tuberculosis ; Age- Unknown; Gender- Both; Country- South Africa; Other- drug-resistant tuberculosis.,pharmacogenomic-guided treatment,Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in  Treatment of Active Tuberculosis.,Standard/Usual Care- Standard treatment,NE
2020-01-30852,2020,Rens 2020 Clin Infect Dis,410,pharmacogenomic-guided treatment VERSUS Standard/Usual Care- Stand treatment IN Specific disease- uberculosis ; Age- Unknown; Gender- Both; Country- Brazil; Other- Drug-resistant tuberculosis.,31905381,Specific disease- uberculosis ; Age- Unknown; Gender- Both; Country- Brazil; Other- Drug-resistant tuberculosis.,pharmacogenomic-guided treatment,Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in  Treatment of Active Tuberculosis.,Standard/Usual Care- Stand treatment,NE
2020-01-30852,2020,Rens 2020 Clin Infect Dis,670,pharmacogenomic-guided treatment VERSUS Standard/Usual Care- Standard treatment IN Specific disease- tuberculosis ; Age- Unknown; Gender- Both; Country- India; Other- drug-resistant tuberculosis..,31905381,Specific disease- tuberculosis ; Age- Unknown; Gender- Both; Country- India; Other- drug-resistant tuberculosis..,pharmacogenomic-guided treatment,Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in  Treatment of Active Tuberculosis.,Standard/Usual Care- Standard treatment,NE
2019-01-31767,2019,Vecoso 2019 Front Pharmacol,Cost-Saving,"oseltamivir + zanamivir VERSUS None IN Healthy; Age- 0 to 18 years, Adult; Gender- Both; Country- Brazil; Other- H1N1 non-vaccinated or vaccinated for less than 15 days; high risk for influenza complications.",31572172,"Healthy; Age- 0 to 18 years, Adult; Gender- Both; Country- Brazil; Other- H1N1 non-vaccinated or vaccinated for less than 15 days; high risk for influenza complications.",oseltamivir + zanamivir,Cost-Effectiveness Analysis of Influenza A (H1N1) Chemoprophylaxis in Brazil.,None,SE
2019-01-31517,2019,Ben 2019 Appl Health Econ Health Policy,1,systematic teleophthalmology-based screening VERSUS Standard/Usual Care- Opportunistic ophthalmology referral-based IN Specific disease- type 2 diabetes; Age- 19 to 40 years; Gender- Both; Country- Brazil; Other- without retinopathy.,31674001,Specific disease- type 2 diabetes; Age- 19 to 40 years; Gender- Both; Country- Brazil; Other- without retinopathy.,systematic teleophthalmology-based screening,Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System.,Standard/Usual Care- Opportunistic ophthalmology referral-based,NE
2019-01-31517,2019,Ben 2019 Appl Health Econ Health Policy,Dominated,systematic ophthalmology referral-based screening VERSUS Systematic teleophthalmology-based IN Specific disease- type 2 diabetes; Age- 19 to 40 years; Gender- Both; Country- Brazil; Other- without retinopathy.,31674001,Specific disease- type 2 diabetes; Age- 19 to 40 years; Gender- Both; Country- Brazil; Other- without retinopathy.,systematic ophthalmology referral-based screening,Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System.,Systematic teleophthalmology-based,NW
2019-01-30195,2019,Aguiar 2019 Einstein (Sao Paulo),150000,abiraterone + androgen deprivation therapy VERSUS Standard/Usual Care- androgen deprivation therapy IN Specific disease- prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Castration-sensitive metastatic prostate cancer.,30843996,Specific disease- prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Castration-sensitive metastatic prostate cancer.,abiraterone + androgen deprivation therapy,"Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.",Standard/Usual Care- androgen deprivation therapy,NE
2019-01-30195,2019,Aguiar 2019 Einstein (Sao Paulo),190000,abiraterone + androgen deprivation therapy VERSUS docetaxel + androgen deprivation therapy IN Specific disease- prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Castration-sensitive metastatic prostate cancer.,30843996,Specific disease- prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Castration-sensitive metastatic prostate cancer.,abiraterone + androgen deprivation therapy,"Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.",docetaxel + androgen deprivation therapy,NE
2019-01-30195,2019,Aguiar 2019 Einstein (Sao Paulo),44000,docetaxel + androgen deprivation therapy VERSUS Standard/Usual Care- androgen deprivation therapy IN Specific disease- prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Castration-sensitive metastatic prostate cancer.,30843996,Specific disease- prostate cancer; Age- Adult; Gender- Male; Country- Brazil; Other- Castration-sensitive metastatic prostate cancer.,docetaxel + androgen deprivation therapy,"Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.",Standard/Usual Care- androgen deprivation therapy,NE
2019-01-29506,2019,Mosegui 2019 J Infect Public Health,Dominated,"Children receive oral rehydration therapy at home VERSUS Children receive oral rehydration therapy at home; If it fails, they will receive supervised ORT. If it also fails, they would receive IVT IN Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.",31104987,Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.,Children receive oral rehydration therapy at home,Cost-effectiveness analysis of oral rehydration therapy compared to intravenous rehydration for acute gastroenteritis without severe dehydration treatment.,"Children receive oral rehydration therapy at home; If it fails, they will receive supervised ORT. If it also fails, they would receive IVT",NW
2019-01-29506,2019,Mosegui 2019 J Infect Public Health,Dominated,"Children receive oral rehydration therapy at home; if it fails, they receive IVT VERSUS Children receive oral rehydration therapy at home; If it fails, they will receive supervised ORT. If it also fails, they would receive IVT IN Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.",31104987,Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.,"Children receive oral rehydration therapy at home; if it fails, they receive IVT",Cost-effectiveness analysis of oral rehydration therapy compared to intravenous rehydration for acute gastroenteritis without severe dehydration treatment.,"Children receive oral rehydration therapy at home; If it fails, they will receive supervised ORT. If it also fails, they would receive IVT",NW
2019-01-29506,2019,Mosegui 2019 J Infect Public Health,Dominated,"Intravenous rehydration therapy VERSUS Children receive oral rehydration therapy at home. If it fails, they receive supervised ORT. If it also fails, they receive Intravenous rehydration therapy IN Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.",31104987,Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.,Intravenous rehydration therapy,Cost-effectiveness analysis of oral rehydration therapy compared to intravenous rehydration for acute gastroenteritis without severe dehydration treatment.,"Children receive oral rehydration therapy at home. If it fails, they receive supervised ORT. If it also fails, they receive Intravenous rehydration therapy",NW
2019-01-29506,2019,Mosegui 2019 J Infect Public Health,Dominated,"Oral rehydration therapy at home VERSUS Children receive oral rehydration therapy at home; If it fails, they will receive supervised ORT. If it also fails, they would receive IVT IN Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.",31104987,Specific disease- Gastroenteritis; Age- 0 to 18 years; Gender- Both; Country- Brazil.,Oral rehydration therapy at home,Cost-effectiveness analysis of oral rehydration therapy compared to intravenous rehydration for acute gastroenteritis without severe dehydration treatment.,"Children receive oral rehydration therapy at home; If it fails, they will receive supervised ORT. If it also fails, they would receive IVT",NW
2019-01-29493,2019,Borba 2019 Value Health Reg Issues,3700,Pegylated interferon + ribavirin VERSUS None IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Brazil.,31108456,Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- Brazil.,Pegylated interferon + ribavirin,Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective.,None,NE
2019-01-29493,2019,Borba 2019 Value Health Reg Issues,8900,Telaprevir + pegylated interferon + ribavirin VERSUS Pegylated interferon + ribavirin IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Brazil.,31108456,Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- Brazil.,Telaprevir + pegylated interferon + ribavirin,Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective.,Pegylated interferon + ribavirin,NE
2019-01-29493,2019,Borba 2019 Value Health Reg Issues,Dominated,Boceprevir + pegylated interferon + ribavirin VERSUS None IN Specific disease- Hepatitis C virus; Age- Adult; Gender- Both; Country- Brazil.,31108456,Specific disease- hepatitis C; Age- Adult; Gender- Both; Country- Brazil.,Boceprevir + pegylated interferon + ribavirin,Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective.,None,NW
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
